AstraZeneca announced positive results of the first large real-world evidence study of its kind evaluating the risk of hospitalization for heart failure and death from any cause in patients with type-2 diabetes receiving treatment with a newer class of diabetes medicines.
The CVD-REAL study assessed data from more than 300,000 patients across six countries, 87 percent of whom did not have a history of cardiovascular disease.
The data showed that across this broad population of patients AstraZeneca’sFarxigareduced the rate of hospitalization for heart failure by 39 percent.
For the composite endpoint of hospitalization for heart failure and death from any cause, the reduction was 46 percent.
Worldwide, diabetes affects around 415 million adults, a number estimated to rise to 642 million by 2040 or one in 10 adults. People with type 2 diabetes have a two to three times greater risk of heart failure and are at an increased risk of having a heart attack or stroke, and some 50 percent of deaths in people with Type 2 are caused by cardiovascular disease.
Bruce Cooper, MD, Vice President and Head of Global Medical Affairs at AstraZeneca, said: “Diabetes is a growing epidemic worldwide, which is associated with significant comorbidities that contribute to an increased risk of costly hospitalizations and even death. Real-world data from this study provide striking evidence that the newer SGLT-2i class of medicines cuts the rate of hospitalizations for heart failure and death by approximately half.”
The hospitalizations for heart failure analysis was conducted using anonymized patient data from Denmark, Germany, Norway, Sweden, United Kingdom and the United States.
Farxiga is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes.
AstraZeneca employs about 1,500 in Delaware.